peripartum cardiomyopathy

in review 4 min read Updated 2026-10-18
peripartum cardiomyopathy

New LVEF <45% toward the end of pregnancy or in the months after delivery (mostly the first month), no other cause. New orthopnoea, PND, hypoxaemia, or pulmonary oedema late in pregnancy/postpartum → urgent echo. Pregnancy HF therapy is restricted (no ACEi/ARB/ARNI/MRA/SGLT2i); after delivery switch to full GDMT with breastfeeding-compatible choices. Next pregnancy: risk scales with residual dysfunction — ≤ mild residual impairment = mWHO 2.0 III, > mild = IV (contraindicated) (ESC 2025); continue β-blocker through it.

recognition

  • Symptoms overlap with normal pregnancy — red flags: orthopnoea/PND, resting hypoxaemia, tachycardia >100 at rest, ↑JVP with crackles, S3 with other signs
  • Risk factors: preeclampsia/HDP, multifetal, age >30, African ancestry, prior PPCM, tocolytics; up to 15% carry DCM variants (TTN truncating most common; FLNC, BAG3, DSP)
  • Workup: ECG, CXR, NT-proBNP (only mildly ↑ in normal pregnancy; <300 ng/L makes acute HF unlikely; no pregnancy-specific cut-off), troponin, TTE (LVEF, LV/RV size, thrombus); CMR (no gadolinium antepartum) if uncertain
  • Differential of pulmonary oedema in pregnancy: preeclampsia (often preserved EF), pre-existing DCM/valve disease unmasked (MS), ischaemia/SCAD, tocolytic- or fluid-induced, sepsis, amniotic fluid embolism

management

antepartumpostpartum (breastfeeding)postpartum (not breastfeeding)
diureticfurosemide (cautious — placental perfusion)furosemidefurosemide
beta-blockermetoprolol (β1-selective); not atenololmetoprololmetoprolol, bisoprolol, carvedilol
afterloadhydralazine + nitrateenalapril or captoprilACEi/ARB → ARNI
MRA✗spironolactone (limited data; generally acceptable)spironolactone/eplerenone
SGLT2i✗✗dapagliflozin/empagliflozin
otherdigoxin if refractory/AF—ivabradine if indicated
  • Acute decompensation: O₂, NIV, IV loop diuretic, nitrates; left lateral position antepartum; avoid excess fluids around delivery (autotransfusion)
  • Cardiogenic shock: ICU, norepinephrine for BP; avoid β-agonists (dobutamine) where possible — PPCM is sensitive to β-stimulation; levosimendan may be considered; early MCS and transfer to a centre with ECMO/LVAD/transplant; urgent delivery after stabilisation
  • Delivery: vaginal with epidural for most stable patients; CS for obstetric indication or haemodynamic instability
  • Anticoagulation: at least prophylactic LMWH with reduced EF and with bromocriptine — high early embolism rate; therapeutic if LVEF <35% (ESC 2025), LV thrombus, AF, or systemic embolism
  • Bromocriptine 2.5 mg BID × 2 wk then daily × 6 wk (severe, LVEF <25% or shock) or 2.5 mg daily × 1 wk (uncomplicated) — ESC-supported, Canadian practice variable; with at least prophylactic LMWH (ESC IIa); suppresses lactation
  • Wearable defibrillator/ICD: LVEF ≤35% early — reassess at 3–6 months before ICD (many recover); early ICD not advised; severe LV dysfunction >6 months despite therapy → ICD ± CRT
medication reconciliation at delivery

The safe list changes at placenta delivery. Antepartum restrictions (ACEi/ARB/MRA) no longer apply → start GDMT postpartum, choosing breastfeeding-compatible agents. Reconcile before discharge.


prognosis and future pregnancy

  • Recovery (LVEF >50%): ~46% at 6 months in the global EORP registry (25–62% by region), ~72% at 12 months in North American IPAC; recovery continues beyond 1 year in some
  • Poor recovery: LVEF <30%, LVEDD >60 mm (IPAC: none with both recovered fully), RV involvement, delayed diagnosis
  • GDMT for 12–24 months after full recovery; then stepwise withdrawal — MRA → ACEi/ARB/ARNI → β-blocker last — with echo every 3–6 months — only if no genetic cardiomyopathy (TTN etc.)
  • Contraception: progestin IUD/implant (avoid oestrogen); breastfeeding not contraindicated if stable
  • Genetic testing if family history, persistent dysfunction, or considering GDMT withdrawal

subsequent pregnancy

LVEF before next pregnancyworsening / relapsematernal mortalityguidance
recovered (≥50%)~20% — often after stopping HF drugslow (~2%)reasonable with cardio-obstetric care; keep β-blocker
≤ mild residual LV impairmentnot clearly higher than recovered in EORP~2% (EORP); older series highermWHO 2.0 III — Pregnancy Heart Team-led care, expert centre
> mild residual LV impairment (≈ LVEF <40%)highhistorically 10–20%mWHO 2.0 IV — advise against pregnancy
  • Continue (or restart) β-blocker for any subsequent pregnancy, regardless of LV recovery — stop ACEi/ARB/MRA/SGLT2i before conception
  • Stress echo showing contractile reserve off HF drugs → favourable
  • Pre-conception cardio-obstetrics review for all
subsequent pregnancy

Recovered LVEF ≠ safe next pregnancy — ~20% still deteriorate, mostly when GDMT is stopped. LVEF alone doesn’t stratify risk well; counsel, keep β-blocker, monitor each trimester and postpartum.


evidence

  • EORP subsequent pregnancy (2025) — 98 pregnancies after PPCM: maternal mortality 2%; baseline LVEF <50% (mostly 40–50%) not associated with more adverse maternal events; LVEF fell in recovered women, linked to GDMT discontinuation
  • IPAC (2015) — n=100 North American PPCM: 72% LVEF ≥50% at 12 months; LVEF <30% + LVEDD ≥60 mm → no full recovery
  • Hilfiker-Kleiner, Eur Heart J. 2017 — bromocriptine 1 wk vs 8 wk (n=63, no placebo): no difference in LVEF recovery; supports dose but not efficacy vs placebo

Prepared 2026-10-18. Not yet verified — check every number against the sources.

Key references

+3 more sources

Suggest a correction peripartum cardiomyopathy